Advanced search
Publication Cover
OncoImmunology Volume 13, 2024 - Issue 1
Submit an article Journal homepage
1,485
Views
0
CrossRef citations to date
0
Altmetric
Original research

Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer

Hélène Poinota School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0009-0006-8347-8430View further author information
ORCID Icon,
Eloïse Dupuychaffraya School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0009-0004-0465-6856View further author information
ORCID Icon,
Grégoire Arnouxc Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandView further author information
,
Montserrat Alvareza School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0001-7206-073XView further author information
ORCID Icon,
Jérémie Tacheta School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-2442-6327View further author information
ORCID Icon,
Ounss Ezzara School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandView further author information
,
Jonathan Moored Translational Research Centre in Oncohaematology, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-7586-671XView further author information
ORCID Icon,
Olivia Bejuye CIBM Center for Biomedical Imaging, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-6457-6717View further author information
ORCID Icon,
Eulalia Olestia School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0001-8677-9964View further author information
ORCID Icon,
Gioele Viscontia School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0003-2486-7744View further author information
ORCID Icon,
Víctor González-Ruiza School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0001-7204-2363View further author information
ORCID Icon,
Serge Rudaza School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-4180-5417View further author information
ORCID Icon,
Jean-Christophe Tillef Division of Clinical Pathology, Geneva University Hospitals, Geneva, SwitzerlandView further author information
,
Clarissa D. Voegelg Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-5480-7956View further author information
ORCID Icon,
Patrycja Nowak-Sliwinskaa School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland;d Translational Research Centre in Oncohaematology, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-8299-0444View further author information
ORCID Icon,
Carole Bourquina School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland;h Department of Anesthetics, Pharmacology, Intensive Care and Emergencies, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3862-4583View further author information
ORCID Icon &
Aurélien Pommiera School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland;b Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, SwitzerlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0001-6540-1863View further author information
ORCID Icon show all
Article: 2286820 | Received 19 Jul 2023, Accepted 20 Nov 2023, Published online: 30 Nov 2023

References

  • Tung I, Sahu A. Immune checkpoint inhibitor in first-line treatment of metastatic renal cell carcinoma: a review of Current evidence and future directions. Front Oncol. 2021;11:707214. doi:10.3389/fonc.2021.707214.
  • Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5(6):e001079. doi:10.1136/esmoopen-2020-001079.
  • Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–11. doi:10.1016/j.ctrv.2018.07.009.
  • Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids—all-Rounders tackling the versatile players of the immune System. Front Immunol. 2019;10:1744. doi:10.3389/fimmu.2019.01744.
  • Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D’Angelo SP, Woo KM, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan Kettering cancer center. J Clin Oncol. 2015;33(28):3193–3198. doi:10.1200/JCO.2015.60.8448.
  • Mahata B, Zhang X, Kolodziejczyk AA, Proserpio V, Haim-Vilmovsky L, Taylor AE, Hebenstreit D, Dingler F, Moignard V, Göttgens B, et al. Single-cell RNA sequencing reveals T helper cells synthesizing steroids De novo to contribute to immune homeostasis. Cell Rep. 2014;7(4):1130–1142. doi:10.1016/j.celrep.2014.04.011.
  • Carter RN, Paterson JM, Tworowska U, Stenvers DJ, Mullins JJ, Seckl JR, Holmes, MC. Hypothalamic-pituitary-adrenal axis abnormalities in response to deletion of 11β-HSD1 is strain-dependent. J Neuroendocrinol. 2009;21(11):879–887. doi:10.1111/j.1365-2826.2009.01899.x.
  • Suzuki T, Moriya T, Ishida T, Ohuchi N, Sasano H. Intracrine mechanism of estrogen synthesis in breast cancer. Biomed Pharmacother. 2003;57(10):460–462. doi:10.1016/j.biopha.2003.09.007.
  • Stuchbery R, McCoy PJ, Hovens CM, Corcoran NM. Androgen synthesis in prostate cancer: do all roads lead to Rome? Nat Rev Urol. 2017;14(1):49–58. doi:10.1038/nrurol.2016.221.
  • Frycz BA, Murawa D, Borejsza‑Wysocki M, Wichtowski M, Spychała A, Marciniak R, Murawa P, Drews M, Jagodziński PP. mRNA expression of steroidogenic enzymes, steroid hormone receptors and their coregulators in gastric cancer. Oncol Lett. 2017;13(5):3369–3378. doi:10.3892/ol.2017.5881.
  • Li CF, Liu TT, Wang JC, Yu SC, Chen YY, Fang FM, Li W-S, Huang H-Y. Hydroxysteroid 11-beta dehydrogenase 1 overexpression with copy-number gain and missense mutations in primary gastrointestinal stromal tumors. J Clin Med. 2018;7(11):408. doi:10.3390/jcm7110408.
  • Slominski RM, Tuckey RC, Manna PR, Jetten AM, Postlethwaite A, Raman C, Slominski AT. Extra-adrenal glucocorticoid biosynthesis: implications for autoimmune and inflammatory disorders. Genes Immun. 2020;21(3):150–168. doi:10.1038/s41435-020-0096-6.
  • Hasan MN, Capuk O, Patel SM, Sun D. The role of metabolic plasticity of tumor-associated macrophages in shaping the tumor microenvironment immunity. Cancers Basel. 2022;14(14):3331. doi:10.3390/cancers14143331.
  • Edwards CRW, Burt D, Mcintyre MA, Kloet ERD, Stewart PM, Brett L, Sutanto, WS, Monder, C. Localisation of 11beta-hydroxysteroid dehydrogenase - tissue-specific protector of the mineralocorticoid receptor. Lancet. 1988;332(8618):986–989. doi:10.1016/S0140-6736(88)90742-8.
  • Zhang Z, Coutinho AE, Man TY, Kipari TMJ, Hadoke PWF, Salter DM, Seckl JR, Chapman KE. Macrophage 11β-HSD-1 deficiency promotes inflammatory angiogenesis. J Endocrinol. 2017;234(3):291–299. doi:10.1530/JOE-17-0223.
  • Spinetti T, Spagnuolo L, Mottas I, Secondini C, Treinies M, Rüegg C, Hotz C, Bourquin C. TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function. OncoImmunology. 2016;5(11):e1230578. doi:10.1080/2162402X.2016.1230578.
  • Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, Storch B, Sandholzer N, Wurzenberger C, Anz D, et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res. 2011;71(15):5123–5133. doi:10.1158/0008-5472.CAN-10-3903.
  • Freeman L, Hewison M, Hughes SV, Evans KN, Hardie D, Means TK, Chakraverty R. Expression of 11β-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106(6):2042–2049. doi:10.1182/blood-2005-01-0186.
  • Chapman KE, Coutinho AE, Zhang Z, Kipari T, Savill JS, Seckl JR. Changing glucocorticoid action: 11β-hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation. J Steroid Biochem Mol Biol. 2013;137:82–92. doi:10.1016/j.jsbmb.2013.02.002.
  • Thieringer R, Le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, Hermanowski-Vosatka A. 11β-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol. 2001;167(1):30–35. doi:10.4049/jimmunol.167.1.30.
  • Bourquin C, Pommier A, Hotz C. Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. Pharmacol Res. 2020;154:104192. doi:10.1016/j.phrs.2019.03.001.
  • Fridman WH, Zitvogel L, Sautès–Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.101.
  • Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–918. doi:10.1038/s41591-020-0839-y.
  • Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. doi:10.1038/nature12213.
  • Hunter RW, Ivy JR, Bailey MA. Glucocorticoids and renal na + transport: implications for hypertension and salt sensitivity: glucocorticoids and renal na + transport. J Physiol. 2014;592(8):1731–1744. doi:10.1113/jphysiol.2013.267609.
  • Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 1-beta hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 1994;105(2):R11–R17. doi:10.1016/0303-7207(94)90176-7.
  • Han D, Yu Z, Zhang H, Liu H, Wang B, Qian D. Microenvironment-associated gene HSD11B1 may serve as a prognostic biomarker in clear cell renal cell carcinoma: a study based on TCGA, RT‑qPCR, western blotting, and immunohistochemistry. Bioengineered. 2021;12(2):10891–10904. doi:10.1080/21655979.2021.1994908.
  • Melo LMN, Herrera-Rios D, Hinze D, Löffek S, Oezel I, Turiello R, Klein J, Leonardelli S, Westedt I-V, Al-Matary Y, et al. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma. J Immunother Cancer. 2023;11(4):e004150. doi:10.1136/jitc-2021-004150.
  • Soulier A, Blois SM, Sivakumaran S, Fallah-Arani F, Henderson S, Flutter B, Rabbitt EH, Stewart PM, Lavery GG, Bennett C, et al. Cell-intrinsic regulation of murine dendritic cell function and survival by prereceptor amplification of glucocorticoid. Blood. 2013;122(19):3288–3297. doi:10.1182/blood-2013-03-489138.
  • Taves MD, Ashwell JD. Glucocorticoids in T cell development, differentiation and function. Nat Rev Immunol. 2021;21(4):233–243. doi:10.1038/s41577-020-00464-0.
  • Acharya N, Madi A, Zhang H, Klapholz M, Escobar G, Dulberg S, Christian E, Ferreira M, Dixon KO, Fell G, et al. Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity. 2020;53(3):658–671.e6. doi:10.1016/j.immuni.2020.08.005.
  • Taves MD, Otsuka S, Taylor MA, Donahue KM, Meyer TJ, Cam MC, Ashwell JD. Tumors produce glucocorticoids by metabolite recycling, not synthesis, and activate tregs to promote growth. J Clin Invest. 2023;133(18): doi:10.1172/JCI164599.
  • Yang H, Xia L, Chen J, Zhang S, Martin V, Li Q, Lin S, Chen J, Calmette J, Lu M, et al. Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity. Nat Med. 2019;25(9):1428–1441. doi:10.1038/s41591-019-0566-4.
  • Chuanxin Z, Shengzheng W, Lei D, Duoli X, Jin L, Fuzeng R, Aiping L, Ge Z. Progress in 11β-HSD1 inhibitors for the treatment of metabolic diseases: a comprehensive guide to their chemical structure diversity in drug development. Eur J Med Chem. 2020;191:112134. doi:10.1016/j.ejmech.2020.112134.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.